NM_000329.3(RPE65):c.444G>T (p.Glu148Asp) is a missense variant predicted to replace glutamate with aspartic acid at amino acid p.148. This variant is absent from gnomAD v4.1.0 (PM2_Supporting). This variant has been reported in at least 2 probands with early onset severe retinal dystrophy who harbored the variant in the compound heterozygous state, confirmed in trans with either the NM_000329.3(RPE65):c.131G>A (p.Arg44Gln) variant (PMID: 15024725), which been classified as pathogenic by the ClinGen LCA / eoRD VCEP, or with the NM_000329.3(RPE65):c.1451G>A (p.Gly484Asp) variant (PMID: 30268864), which has been classified as likely pathogenic by the ClinGen LCA / eoRD VCEP (total 2 points, PM3_Strong). The variant has been reported to segregate with childhood-onset severe retinal dystrophy through the proband plus 1 similarly affected relative, with the variant present in the compound heterozygous state (PP1; PMID: 15024725, VCEP member-provided data). The computational predictor REVEL gives a score of 0.696, which is above the ClinGen LCA/eoRD VCEP threshold of ≥0.644 and predicts a damaging effect on RPE65 function (PP3). The splicing impact predictor SpliceAI gives a score of 0.06 for acceptor loss, which is below the ClinGen LCA / eoRD VCEP recommended threshold of ≥0.2 and does not strongly predict an impact on splicing. Introducing the equivalent Glu150Asp substitution into the SynACO enzyme (an ortholog from the unicellular bacterium Synechocystis) reduced its catalytic efficiency to ~9% of the wild-type enzyme (PMID: 34607013). However, PS3_Supporting is not met as this functional assay has not yet been approved by the ClinGen LCA / eoRD VCEP. In summary, this variant meets the criteria to be classified as likely pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PM2_Supporting, PM3_Strong, PP1, and PP3. (VCEP specifications version 1.0.0; date of approval 09/21/2023).